A study of Foundation Year doctors' prescribing in patients with kidney disease at a UK renal unit: A comparison with other prescribers regarding the frequency and type of errors by Patel, Rakesh et al.
A study of Foundation Year doctors’ prescribing
in patients with kidney disease at a UK renal unit:
a comparison with other prescribers regarding
the frequency and type of errors
Rakesh Patel,1 William Green,2 Maria Martinez Martinez,3
Muhammad Waseem Shahzad,4 Chris Larkin4
1Department of Medical and
Social Care Education,
University of Leicester,
Leicester, UK
2School of Management,
University of Leicester,
Leicester, UK
3University Hospitals of
Leicester NHS Trust, Leicester,
UK
4Health Education East
Midlands, Leicester, UK
Correspondence to
Dr Rakesh Patel, Department
of Medical and Social Care
Education, 107 Princess Road
East, Leicester LE1 7LA, UK;
rp299@le.ac.uk
Received 3 December 2014
Revised 20 February 2015
Accepted 24 February 2015
Published Online First
31 March 2015
To cite: Patel R, Green W,
Martinez MM, et al. Eur J
Hosp Pharm 2015;22:
291–297.
ABSTRACT
Objectives Errors in prescribing can cause avoidable
harm to patients. Establishing the extent of prescribing
errors across medical specialties is critical. This research
explores the frequency and types of prescribing errors
made by healthcare professionals prescribing for patients
with renal disease where prescribing problem-solving
and decision-making is complex due to comorbidity.
Methods All prescriptions and errors made by
prescribers were captured over a 4-month period in a UK
renal unit. Data were recorded concerning the medicine
associated with the error, the type and severity of the
error, and the prescriber’s occupational grade.
Results 10 394 prescribed items were captured and
3.54% had associated prescribing errors. While
Foundation Year 1 doctors made almost one error each
week (mean 15.13) and Foundation Year 2 doctors one
every 2 weeks (mean 8.00), other prescribers made one
error per month (mean 3.94). The medicines most
frequently associated with errors for Foundation doctors
were paracetamol (6.51%), calcium acetate (5.33%),
meropenem (3.55%), alfacalcidol (3.55%) and tazocin
(3.55%), while for all other prescribers they were
meropenem (6.15%), alfacalcidol (4.62%), co-amoxiclav
(4.62%) and tacrolimus (4.62%). The most common
types of error for both groups were omitting the
indication, using the brand name inappropriately, and
prescribing inaccurate doses.
Conclusions The range of errors made by multi-
professional healthcare prescribers confirms the
complexity of prescribing on a renal unit for patients
with kidney disease and multimorbidity. These findings
have implications for the types of educational
interventions required for reducing avoidable harm and
overcoming human factors challenges to improve
prescribing behaviour.
INTRODUCTION
Patients with kidney disease across the spectrum of
acute kidney injury through to chronic kidney
disease (CKD) requiring renal replacement therapy
are particularly vulnerable to avoidable harm from
medication.1 2 Patients with CKD tend to be older
than the general population and so have more long
term conditions and multimorbidity which requires
management with medication.3 4 As a consequence
of this disease burden, patients with CKD are also
likely to be prescribed several different medicines
(polypharmacy).5 Increased patient age,
multimorbidity and polypharmacy all lead to a
greater risk of adverse reactions, so preventing
avoidable harm from medication in this group of
patients is particularly important.6 Medicine dose
and dose interval adjustments are an important part
of this strategy. However, calculations can be com-
plicated and the risk of potential harm from pre-
scribing errors remains.1 7 8 Furthermore, some of
the medicines used in renal medicine and transplant-
ation are subject to clinically significant drug and
food interactions that can also result in patient
harm. Consequently, patients with kidney disease
are vulnerable to avoidable harm and adverse events
due to complications from incorrectly prescribed
medicines.
Safe prescribing is a key element of any patient
safety initiative. Dean et al defined a prescribing
error as “an unintentional significant (1) reduction
in the probability of treatment being timely and
effective or (2) increase in the risk of harm when
compared with generally accepted practice” (ref. 9,
p. 235). Prescribing errors are common in the work-
place, with reported rates of between 7% and
15%.10 11 Establishing the type of prescribing errors
in relation to the professional group and occupa-
tional grade of the prescriber provides a more
nuanced understanding of the problem. In a study
of prescribing errors in hospital inpatients in the
UK, Dean et al observed that junior doctors were
responsible for the greatest proportion of errors.12
Dornan et al13 reported that doctors in the first
2 years of qualified practice were more likely to
make a prescribing error compared to other prescri-
bers such as consultants, nurses or pharmacists.
These differences in prescriber occupation warrant
further attention since there is evidence that phar-
macists make almost no medical errors when pre-
scribing.14 The findings of Dornan et al13 also
suggest that the prescribing behaviour of prescribers,
particularly Foundation Year (FY) doctors, requires
close attention, with hospital admission associated
with a greater risk that patients may experience a
prescribing error.
Given the potential threat to patient safety posed
by inexperienced FY doctors (doctors in their first
2 years of practice following graduation from
medical school in the UK), increasing the effective-
ness of their prescribing is paramount. A variety of
educational interventions to improve prescribing
competency have been proposed. In a recent sys-
tematic review, Kamarudin et al15 found that most
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evidence supported the use of the WHO Guide to Good
Prescribing for improving prescribing competence in medical
professionals. They also reported that continuing education and
personalised feedback produce positive results.15
Alongside these educational interventions, references sources
such as the Renal Drug Handbook16 and the electronic
Medicines Compendium17 also support FY doctors prescribing
for patients with kidney disease. While these resources can be
found in the workplace, it remains unclear whether making
more supports available can help FY doctors prescribe safely in
patients with kidney disease. FY doctors perceive renal medicine
as difficult and challenging, particularly around acid-base and
electrolyte disorders and dialysis.18 As a result, Jhaveri et al18
suggest that alternate and innovative methods of teaching renal
medicine are necessary, however there are few alternatives to
traditional textbooks or manuals on how to prescribe in patients
with kidney disease.
Jhaveri et al18 found that FY doctors wanted more practical
prescribing education and explicit feedback on their general pre-
scribing performance. Consequently, the prescribing perform-
ance of individuals in each prescribing context needs to be
studied. Besides informing a targeted programme of education,
elucidating the type of prescribing errors and the most common
medicines involved will provide guidance on how best to design
and deliver education in partnership with other health profes-
sionals such as pharmacists and nurses.
The prevalence of prescribing errors has been widely
reported.2 8 10–13 19–22 However, there is little information
about the nature of the problem in specific prescribing contexts
such as renal units or among patients with renal disease.
Without this context specificity, knowledge of prescribing errors
for informing targeted educational interventions is limited.
Although the type of prescribing errors observed in a renal unit
has been previously reported in a study from Iran, there is no
research specifically exploring the prevalence and type of pre-
scribing errors among FY doctors in the UK.22
The aim of this research was to explore the types of errors in
relation to the medicines involved, and the type and severity of
errors made by FY doctors when prescribing in patients with
kidney disease. This information will provide a better under-
standing of the educational needs around the prescribing of FY
doctors working in UK renal units compared with other health-
care professionals.
METHODS
Context
Clinical pharmacists reviewed all handwritten medicine prescrip-
tions on inpatient medication charts over a 4-month FY doctor
rotation period from April to the end of July 2013. The study
was undertaken in four inpatient wards with a total of 59 beds
in a tertiary centre renal unit at a UK teaching hospital in the
East Midlands. All patients were admitted under specialist renal
care.
Data collection and analyses
A paper-based data collection form adopted from Dornan et al13
was designed and piloted for 7 days to ensure the team of six renal
clinical pharmacists could reliably and practically use it for identify-
ing and coding medication errors. Prior to the study, the clinical
pharmacists received training on capturing data and categorising
error severity. Medicine prescribing errors were recorded during
the usual review of medical charts undertaken by ward-based phar-
macists to minimise disruption to clinical service. All prescribing
errors were recorded alongside the demographic details of the
patient, prescriber details and location when making the prescrip-
tion, and details of the medicine prescribed. All prescribing errors
detected were corrected as part of the pharmacists’ clinical role in
the unit. In order to determine the number of errors as a propor-
tion of the number of total prescriptions, the total number of
medicine prescribed over the 4-month period was recorded daily
from Monday to Friday. All error forms were peer reviewed by
one of the senior renal pharmacists to ensure the accuracy of data.
Another senior renal clinical pharmacist peer reviewed the com-
pleted forms, and gained consensus from the wider team about the
potential for patient harm if the error was undetected. The renal
function of patients in whom errors were detected was calculated
using the Cockroft-Gault equation and the appropriate medication
resource consulted to determine the correct dosing (Renal Drug
Handbook,16 electronic Medicines Compendium,17 Micromedex
and local guidelines). Data were anonymised prior to entry into a
spreadsheet for analyses. A limitation of data collection from hand-
written charts meant that it was not feasible to collect prescriber
information for every prescription made, and so the total number
of prescriptions made per prescriber was not captured in this study.
All errors were grouped according to the medicine name and
error type for both FY doctors and all other prescribers.
All errors were further categorised using the EQUIP criteria.13
All serious or lethal errors (those involving erythropoiesis-
stimulating agents, antibiotics and phosphate binders) were
reported in more depth. The prescribing errors were categorised
into 37 error types.13
The study was completed as part of the University Hospitals
of Leicester NHS Trust’s commitment to ensuring patient safety
and improving quality. The study was registered with the clinical
effectiveness team in the trust, reference number 6608E.
Therefore, all issues related to perceptions of surveillance and
temporary behaviour changes were minimised.
The results are compared between FY doctors and all other
prescribers (senior trainees, nurses, a dietician, consultants and
core trainees) under six headings: total number of errors, medi-
cines associated with errors, type of error, type of renal-specific
error, severity of error, medicines specific to kidney disease, and
antibiotics.
The most junior members of the medical team only complete
prescriptions using a computer at patient discharge and so any
errors had a potentially different aetiology from those associated
with handwritten charts. Discharge data were therefore
excluded from analyses.
RESULTS
Total number of errors
A total of 10 394 prescribed items were captured during the
4-month study. The pharmacy team identified 368 (3.54%) as
having prescribing errors. Some errors were removed from the
analyses due to missing information, as follows:
▸ 56 (15.2%) errors were not attributable to any prescriber
due to signatures being omitted, unknown or unreadable.
▸ 13 (3.5%) errors were attributable to FY doctors not rou-
tinely based on the renal unit. These prescriptions were
likely written by doctors during on-call shifts, or when
patients were elsewhere.
The FY doctors (n=14) made 169 (56.52%) prescribing
errors, while all other prescribers (n=33) made 130 (table 1).
Therefore, Foundation Year 1 (FY1) doctors individually made
almost four times as many prescribing errors as all other prescri-
bers and twice as many as Foundation Year 2 (FY2) doctors,
while FY2 doctors made twice as many prescribing errors as all
other prescribers.
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Medicines associated with prescribing errors
The 299 prescription errors concerned 115 different medicines.
Table 2 lists the most common medicines involved in prescribing
errors by order of prevalence. The most common medicines for
the FY doctors were paracetamol and calcium acetate, while for
all other prescribers they were meropenem, alfacalcidol,
co-amoxiclav and tacrolimus. More than half of the medicines
(n=65) were associated with only one error.
Type of error
An additional 37 errors were included for a total of 336 errors
as 32 errors had two error types and five had three error types.
Table 3 shows the 10 most common error types by order of
prevalence, with an example for each. The top three error types
were the same for the FY doctors and all other prescribers, and
were ‘omission—indication’, ‘brand name’ and ‘wrong dose’.
Renal specific errors
Examples of prescribing errors specific to kidney disease are
provided in table 4.
Potential severity of error
The potential severity of error was similar between the FY and
other prescriber groups (table 5), with a similar percentage of
minor and significant errors and fewer serious errors. One lethal
error, attributed to a FY2 doctor, concerned the
immunosuppressant medicine tacrolimus with 500 mg pre-
scribed rather than 500 micrograms.
Medicines specific to kidney disease
Erythropoiesis-stimulating agents were associated with 5.02% of
errors (n=15). The medicines involved were darbepoetin alfa
(FY, n=4; others, n=5), epoetin alfa (FY, n=3; others, n=2)
and erythropoietin (FY, n=1).
Phosphate binders were involved in almost 9% of errors
(n=24) (table 6). Calcium acetate was the most common bone
biochemistry medicine associated with prescribing errors. Nine
phosphate binders prescribing errors were classified as minor
(36%), 14 as significant (60%) and one as serious (4%).
Antibiotics
Almost 20% of errors (n=58) concerned antibiotics (table 7),
with meropenem and tazocin involved in almost 25% of these,
followed by doxycycline and co-amoxiclav (19%). These per-
centages were relatively consistent for FY doctors and all other
prescribers.
DISCUSSION
This is the first study to explore the prescribing behaviour of
healthcare professionals, in particular FY doctors, working in a
renal unit in the UK. The study found that over the 4-month
observation period, FY1 doctors made four times and FY2
doctors twice as many errors as other healthcare professionals.
This supports prior research reporting that FY doctors make
more errors individually than other prescribers.12 13 It is not
possible to quantify the extent of this problem without knowing
the proportion of prescriptions written by both groups.
Nonetheless, the findings suggest that FY doctors would benefit
from educational interventions tailored to their specific learning
needs.15
Paracetamol was the medicine most frequently associated with
a prescribing error, with FY doctors making proportionally
twice as many errors as other healthcare professionals.
Paracetamol was previously found to be one of the five most
common incorrectly prescribed medicines in UK critical care
units,21 with FY doctors proportionally making far more errors
Table 1 Prescribing error frequency by occupational group
Prescriber occupational grade
All other
prescribers
Foundation
Year 1
Foundation
Year 2
Prescribers (n) 8 6 33
Errors 121 (40.47%) 48 (16.05%) 130 (43.48%)
Mean number of errors
per prescriber
15.13 8.00 3.94
Table 2 Medicines most commonly involved in a prescribing error by rank for group, number of observed prescribing errors and percentage
within prescribing group
Total Foundation Year 1 and 2 All other prescribers
Rank Observed Percentage Rank Observed Percentage Rank Observed Percentage
Paracetamol 1 15 5.02% 1 11 6.51% 9 4 3.08%
Calcium acetate 2 14 4.68% 2 9 5.33% 4 5 3.85%
Meropenem 2 14 4.68% 3 6 3.55% 1 8 6.15%
Alfacalcidol 4 12 4.01% 3 6 3.55% 2 6 4.62%
Tazocin 5 11 3.68% 3 6 3.55% 4 5 3.85%
Co-amoxiclav 5 11 3.68% 6 5 2.96% 2 6 4.62%
Tacrolimus 7 10 3.34% 9 4 2.37% 2 6 4.62%
Darbepoetin alfa 8 9 3.01% 9 4 2.37% 4 5 3.85%
Dalteparin 9 8 2.68% 15 3 1.78% 4 5 3.85%
Insulin 10 7 2.34% 6 5 2.96% 15 2 1.54%
Flucloxacillin 10 7 2.34% 15 3 1.78% 9 4 3.08%
Sando-K 13 6 2.01% 9 4 2.37% 15 2 1.54%
Zopiclone 12 6 2.01% 9 4 2.37% 15 2 1.54%
Sevelamer 14 5 1.67% 6 5 2.96% 0 0 0.00%
Epoetin alfa 14 5 1.67% 15 3 1.78% 15 2 1.54%
Metronidazole 14 5 1.67% 32 1 0.59% 9 4 3.08%
Novomix 30 14 5 1.67% 32 1 0.59% 9 4 3.08%
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related to paracetamol than other healthcare professionals.
While paracetamol is freely available over the counter and is
often considered to require no specific prescription knowledge,
it must be used cautiously in certain patient groups and dose
adjusted in patients with lower weight. While only 10% of
errors in this study were related to dosing, percentages of up to
43% were previously reported.8 Dornan et al found FY doctors
did not mention safety when discussing their errors,13 and so
the lack of safe prescribing behaviours may help explain the
observed error rate identified in this study.
Medicines usually associated with kidney disease
(erythropoiesis-stimulating agents, phosphate binders and
immunosuppressive drugs) were involved in a third of all pre-
scribing errors. This suggests two things. First, prescribing in
patients with renal disease is challenging due to the complexity
involved1–7 irrespective of the clinical experience of the pre-
scriber. Second, patients with renal disease experience prescrib-
ing errors for reasons likely unrelated to the complexity of their
condition or a prescriber’s lack of knowledge of renal medicine.
Possible explanations for errors made by prescribers may relate
to human factors, for example, “slips in attention, memory
lapses, the effects of workload and environment, interruptions,
hierarchies and poor communication” (ref. 23, p. 455). Further
research is required to establish the relevant individual, social,
contextual and environmental factors and what educational and
organisational interventions can be developed to overcome
them.
The error types identified in this study confirm that FY
doctors and other prescribers are equally prone to making
errors related to omission, wrong dosage and using brand
names for medicines. This seems to be a generic problem across
all prescribers irrespective of clinical context as confirmed by
Taylor et al24 who reported similar outcomes after investigating
errors on handwritten prescription charts in a paediatric emer-
gency department. Comparisons of error type are difficult since
coding classification is heterogeneous and there is little stand-
ardisation of coding or definitions across studies.
Using the brand name when prescribing medicines is an error
in some prescribing contexts. However, in other contexts not
prescribing using brand names can cause significant patient
safety issues.25 For example, prescribing using the brand name is
a policy requirement for specific transplantation medicines, such
as tacrolimus. In this case, an inadvertent brand switch could
cause clinically significant negative outcomes such as transplant
rejection or drug toxicity. These conflicting guidelines—requir-
ing a brand name in some cases but discouraging it in others—
can be a potential source of error for novice prescribers.
Although there may be an issue with associating the use of
brand names with prescribing errors, references such as the
Renal Drug Handbook and the electronic Medicines
Compendium include clear information and guidance on medi-
cation dosing in renal medicine. Although these resources were
available in the renal unit, wrong dosage was a frequent and
consistent problem irrespective of the type of prescriber. This
suggests that the problem is related to human factors issues
which should be identified by further research on systemic
factors surrounding prescribing.
This study found the majority of prescribing errors had the
potential for minor or significant harm, consistent with prior
studies.13 21 As a proportion of all prescriptions, fewer errors
were found (3.54%) in this study compared with more general
prescribing contexts. For example, Ridley et al21 reported an
error rate of 14.55% over a 4-week period in 24 critical care
units, and Dornan et al13 reported an error rate of 8.91% over
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seven ‘census days’ in a study of 19 acute hospital trusts. The
wide range in error rate observed in these studies should be the
subject of further research. The variation may reflect differences
in prescribing contexts across situations, such as level of prescrib-
ing support for healthcare professionals, prescribing experience,
and familiarity with the patient population by the prescriber.
While the clinical supervision of FY doctors by senior
medical doctors is well established, the educational input by
pharmacists remains underutilised in terms of formal teaching
and learning. The type of renal-specific errors suggests context-
specific knowledge is crucial to reduce severe and lethal errors.
Pharmacist-led interventions help reduce prescribing errors
among FY doctors and could do so in specialist contexts.26
Furthermore, clinical pharmacists already contribute to under-
graduate education,27 so extending their role across the con-
tinuum of medical education may be a cost-effective strategy for
reducing avoidable harm in complex clinical settings such as the
renal unit. Further research is necessary to establish the
feasibility of using pharmacists for delivering medical education,
given the significant pressures clinical pharmacy services face.
Nevertheless, in light of the consistency of findings suggesting
FY doctors are error prone, the risk to patient safety from pre-
scribing errors in complex settings may warrant additional
resources.
There are two main limitations to this research. First, sub-
group analysis between professional groups was not possible as
the total number of prescriptions made by each prescribing
group was not known. While prescription errors by individual
medicine name were known for each prescriber, the total
number of prescriptions for each medicine was unknown, so cal-
culating relative risk by medicine name was not possible.
Without this information, this study was unable to establish
whether the error rate of FY doctors in relation to the propor-
tion of prescriptions is higher than for other prescribers, or to
ascertain which medicine is associated with the highest rate of
prescribing errors.
Table 4 Error type for renal-specific errors, categorised by type of medication, error description, potential negative outcome and severity
Medication category Error description Potential negative outcome Severity
Medicines used in chronic
kidney disease
Prescription for ‘Epo’. Inappropriate abbreviation used with no
brand or dose specified
Prescription is unclear and therefore nursing staff would be
unable to administer the medication. As a consequence, the
patient may not receive the treatment or it could lead to
inappropriate delays.
Severe
Calcium carbonate prescribed as a phosphate binder for a
patient with hypercalcaemia
Exacerbation of hypercalcaemia potentially causing lethargy,
weakness, confusion, coma, constipation, nausea, anorexia and
arrhythmias
Severe
Anticoagulation Dalteparin (12 500 units once daily) prescribed for a deep
venous thrombosis in a patient on haemodialysis
Low molecular weigh heparins given at conventional treatment
doses to patients on haemodialysis will accumulate, which can
complicate reversal of anticoagulation.
Severe
Antimicrobials Clarithromycin prescribed in combination with tacrolimus and
atorvastatin (significant interactions)
Increased exposure to atorvastatin and tacrolimus, which could
lead to myopathy (atorvastatin) and nephrotoxicity and
neurotoxicity (tacrolimus)
Severe
Wrong dose of ganciclovir prescribed (500 mg tds instead of
500 mg bd)
Increased exposure to ganciclovir, which could lead to
neurotoxicity and myelosuppression
Severe
Incorrect (too high) dose of meropenem prescribed for a
patient receiving haemodialysis
Increased exposure to meropenem which could lead to
neurotoxicity
Severe
Valganciclovir unintentionally omitted from a renal transplant
patient medication card when it was required
Omitting valganciclovir in these cases could result in increased
risk of cytomegalovirus disease
Severe
Immunosuppression Treatment with mycophenolate mofetil inadvertently continued
for a renal transplant patient with cytomegalovirus infection
If immunosuppression is not minimised, this could compromise
the success of treatment for cytomegalovirus disease in renal
transplant patients.
Severe
New transplant patient whose medication chart did not include
any immunosuppression or adjuvant agents given after renal
transplantation. This patient was prescribed inappropriate
medicines such as high-dose furosemide and phosphate binders
(no longer indicated)
Lack of prescribed immunosuppression following renal
transplantation will increase the risk of acute rejection and graft
loss.
Severe
Prograf dose prescribed as 500 mg instead of 500 micrograms Although it is unlikely that the dose would have been given
(100 capsules of 5 mg would have to be administered), this error
constitutes a 1000-fold overdose which would almost certainly
be fatal.
Lethal
Table 5 Prescription errors by potential severity of error
Potential severity of error Example Total
Foundation
Year 1 and 2
All other
prescribers
Minor Simvastatin prescribed in the morning rather than at night 129 43.14% 66 39.05% 63 48.46%
Significant No maximum frequency stated when paracetamol prescribed 124 41.47% 73 43.20% 51 39.23%
Serious Co-amoxiclav prescribed to patient with known penicillin allergy 45 15.05% 29 17.16% 16 12.31%
Lethal 500 mg of tacrolimus prescribed instead of 500 micrograms 1 0.33% 1 0.59% 0 0.00%
Total 299 100% 169 100% 130 100%
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Second, the design of the study was limited to a time period
corresponding to a single rotation of doctors and a single centre
where handwritten drug charts were used for prescribing medi-
cation. Hospitals are increasingly adopting computerised
systems to support prescribing, which reduces the potential for
adverse medicine events,28 particularly in outpatient settings for
patients with CKD. However, these systems are not error free
and have not always been subject to rigorous evaluation.29
Minor and significant errors can be eradicated with electronic
prescribing, but timesaving workarounds could be used to con-
tinue to omit information, depending on how well the systems
are designed. Renal-specific errors are unlikely to be eradicated
and should be considered in the design of future computerised
systems. Given that electronic prescribing is being more widely
adopted, further research will be required into its effects on the
types of medicines involved in prescribing errors, the type of
prescribing errors when using these electronic prescribing
systems, and the implications this has for the targeting of educa-
tion and human factors interventions.
All final year medical students in the UK are now expected to
successfully complete the Prescribing Skills Assessment in order
to progress into the Foundation Programme.30 This assessment
measures basic level competence upon entry into the workplace,
but there are no further assessments thereafter. So the prescrib-
ing performance of FY doctors is generally not checked after
medical school. Although formal assessments may be impractical
in the postgraduate setting, workplace-based assessments around
prescribing are established and could be used more extensively
to ensure FY doctors have the knowledge, skills and attitudes
required for safe prescribing.
The differences in prescribing errors between professional
groups in this study suggest targeted practice-based education
for FY doctors is necessary to improve prescribing performance,
especially in complex settings like a renal unit. Furthermore, the
educational role of clinical pharmacists should be developed
given they have significant specialty-specific domain knowledge
and currently have limited input into postgraduate medical edu-
cation. Although the role of the pharmacist is well established in
the context of medicines reconciliation, a larger multi-site and
multi-context study is needed to evaluate the effectiveness of
pharmacist-led education for FY doctors in complex clinical
areas.
The high frequency of prescribing errors made by FY doctors
compared with senior healthcare professionals is consistent with
findings from previous studies. The proportion of errors per
prescriber appears to reflect the clinical experience of the pre-
scriber, suggesting educational interventions should focus on
developing prescribing competence rather than increasing
subject- or domain-specific knowledge. Any educational inter-
vention must also consider human factors issues given that
errors can be caused by situational and systematic factors.
Although a third of prescribing errors were associated with med-
icines specifically prescribed for patients with kidney disease,
two-thirds related to generic or commonly prescribed medicines
such as paracetamol. These common errors were similar for FY
doctors and for other prescribers, so the findings have implica-
tions for the development of renal-specific prescribing educa-
tion as well as prescribing education in general. Nevertheless,
FY doctors specifically make prescribing errors that are poten-
tially significant for patients in a renal unit compared to other
areas. Therefore, educational interventions should be imple-
mented in practice-based settings where pharmacists are
present and already play important roles in medicines safety
on the ward. A standardised system for categorising prescrib-
ing errors must be adopted to enable comparisons across
interventions.
Table 6 Phosphate binders most commonly associated with prescribing errors
Phosphate binder
Total Foundation Year 1 and 2 All other
Rank Observed Percentage Rank Observed Percentage Rank Observed Percentage
Calcium acetate 1 14 56.00% 1 9 50.00% 1 5 71.43%
Sevelamer 2 5 20.00% 2 5 27.78% 3 0 0.00%
Lanthanum carbonate 3 4 16.00% 3 3 16.67% 2 1 14.29%
Adcal D3 4 1 4.00% 4 1 5.56% 3 0 0.00%
Total 24 100% 18 100% 6 100%
Table 7 Antibiotic medicines most commonly associated with prescribing errors
Antibiotic medicine
Total Foundation Year 1 and 2 All other prescribers
Rank Observed Percentage Rank Observed Percentage Rank Observed Percentage
Meropenem 1 14 24.14% 1 6 20.69% 1 8 27.59%
Tazocin 2 11 18.97% 2 5 17.24% 2 6 20.69%
Co-amoxiclav 2 11 18.97% 2 5 17.24% 2 6 20.69%
Flucloxacillin 4 7 12.07% 4 3 10.34% 4 4 13.79%
Metronidazole 5 5 8.62% 8 1 3.45% 4 4 13.79%
Doxycycline 6 4 6.90% 4 3 10.34% 6 1 3.45%
Clarithromycin 7 2 3.45% 6 2 6.90% 7 0 0.00%
Pyrazinamide 7 2 3.45% 6 2 6.90% 7 0 0.00%
Rifampicin 9 1 1.72% 8 1 3.45% 7 0 0.00%
Rifinah 9 1 1.72% 8 1 3.45% 7 0 0.00%
Total 58 100% 29 100% 29 100%
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Key messages
What is already known on this subject
▸ Prescribing errors, especially among Foundation Year doctors
(doctors who are in their first 2 years of practice following
graduation from medical school in the UK), are common and
an avoidable cause of adverse harm involving medication.
▸ Prescribing medicines to patients with kidney disease is
complex and challenging due to the high prevalence of
multimorbidity and the greater risks associated with
polypharmacy.
▸ There is little research exploring the type of prescribing
errors in patients with kidney disease.
What this study adds
▸ Prescribing errors in a specialist renal unit were compared to
findings from other studies and found to contain a higher
proportion with the potential to cause severe consequences.
▸ The quantity of prescribing errors among Foundation Year
doctors was associated with their years of clinical
experience: Foundation Year 1 doctors made twice the
number of errors as Foundation Year 2 doctors, and
Foundation Year 2 doctors made twice the number of errors
as other prescribers.
▸ Paracetamol was most frequently associated with prescribing
errors made by Foundation Year doctors.
▸ Further research is required to develop appropriate
interventions based on the findings of this study and identify
educational solutions to the human factors elements in
prescribing errors.
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